详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Brain metastases from non-small cell lung carcinoma: Changing concepts for improving patients' outcome

144| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [a]Department of Radiotherapy, Lucien Neuwirth Cancer Institute, 108 bis, Avenue Albert Raimond, BP 60008, 42271 Saint-Priest en Jarez, France [b]Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon, IPNL, 69622 Villeurbanne, France [c]Department of Radiotherapy, Sichuan Cancer Hospital, 55 Renmin Nan Lu, Sect 4. Wuhou District, Chengdu, 610041, China [d]Department of Radiotherapy, Institut Gustave Roussy, 114, Rue Edouard Vaillant, 94805 Villejuif, France [e]Institut de Recherche Biomédicale des Armées, D19, 91220 Brétigny sur Orge, France [f]French Military Health Services Academy, Ecole du Val-de-Grâce, Paris, France

出处：

DOI：

ISSN：

关键词： Brain metastases Surgery Whole brain radiation therapy Stereotactic radiotherapy Targeted therapy agents

摘要：

The management of Non Small Cell Lung Cancer (NSCLC) brain metastases is challenging, as this frequent complication negatively impacts patients' quality of life, and can be a life-threatening event. Through a review of the literature, we discuss the main therapeutic options and the recent developments that improved (and complicated) the management of NSCLC brain metastases patients. Most current validated approaches are local with exclusive or combined surgery, whole brain radiotherapy (WBRT) and stereotactic radiotherapy (SRT). At the same time, there is a growing role for systemic treatments that might significantly postpone WBRT. Targeted therapies efficacy/toxicity profile remains to be defined but predictive and prognostic molecular factors integration could help to select treatments fully adapted to life expectancy and progression risk. (C) 2017 Elsevier B.V. All rights reserved.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版中科院分区表Review为是的期刊

：

大类 | 2 区医学

小类 | 2 区血液学 2 区肿瘤学

最新[2023]版

：

大类 | 2 区

医学

小类 | 2 区血液学 2 区肿瘤学

JCR分区：

出版当年[2017]版：

Q1 HEMATOLOGY Q2 ONCOLOGY

最新[2023]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 5.5 最新[2023版] 5.3 最新五年平均 4.495 出版当年[2017版] 4.413 出版当年五年平均 4.971 出版前一年[2016版] 5.012 出版后一年[2018版]

第一作者：

第一作者机构： [a]Department of Radiotherapy, Lucien Neuwirth Cancer Institute, 108 bis, Avenue Albert Raimond, BP 60008, 42271 Saint-Priest en Jarez, France

通讯作者：

通讯机构： [a]Department of Radiotherapy, Lucien Neuwirth Cancer Institute, 108 bis, Avenue Albert Raimond, BP 60008, 42271 Saint-Priest en Jarez, France [b]Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon, IPNL, 69622 Villeurbanne, France [*1]Lucien Neuwrith Cancer Institute, 108 bis, AvenueAlbert Raimond, BP 60008, 42270 Saint-Priest en Jarez cedex, France.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Brain metastases from non-small cell lung carcinoma: Changing concepts for improving patients' outcome [2]Clinical Features of Brain Metastases in Small Cell Lung Cancer: an Implication for Hippocampal Sparing Whole Brain Radiation Therapy [3]Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: Results & reflections from the prematurely closed phase III HYBRID trial [4]Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial. [5]Corrigendum to “Clinical Features of Brain Metastases in Small Cell Lung Cancer: an Implication for Hippocampal Sparing Whole Brain Radiation Therapy”. [Transl. Oncol. 10(1) 2017:54-58] (S1936523316301693) (10.1016/j.tranon.2016.11.002)) [6]Stereotactic Radiosurgery with Whole Brain Radiotherapy Combined with Bevacizumab in the Treatment of Brain Metastases from NSCLC. [7]Whole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer [8]Brain metastases from carcinoma of uterine cervix [9]Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics. [10]Brain metastases in women with epithelial ovarian cancer: multimodal treatment including surgery or gamma-knife radiation is associated with prolonged survival.